


LIVERPOOL CHIROCHEM


Molecules of the Month

This month's MOTM are Glasdegib (PF-04449913) and Talazoparib (BMN-673)



Talazoparib (BMN-673)
A3040

Talazoparib (BMN-673) is an orally available poly ADP ribose polymerase (PARP) inhibitor currently in development by Pfizer for the treatment of advanced breast cancer patients with germline BRCA mutations. Talazoparib is similar to the first in class PARP inhibitor, olaparib. However, talazoparib is thought to be more potent than olaparib. Talazoparib was originally developed by BioMarin Pharmaceutical Inc. However, Medivation Inc. acquired all worldwide rights to talazoparib in August 2015 to expand their global oncology franchise. Medivation acquired talazoparib for \$410 million with additional payments of up to \$160 million in royalties and milestones. Under this agreement, Medivation assumed all financial responsibilities for the continued development, regulatory, and commercialization of talazoparib.



Glasdegib (PF-04449913)
A3017

Glasdegib (PF-04449913) is an experimental cancer drug developed by Pfizer. It is a small molecule inhibitor of the Sonic hedgehog pathway, which is over-expressed in many types of cancer. It inhibits smoothed receptor, as do most drug in its class. Four phase II clinical trails are in progress. One is evaluating the efficacy of Glasdegib in treating myelofibrosis in patients who were unable to control the disease with ruxolitinib. Another is a combination trial of Glasdenib with ARA-C, decitabine, daunorubicin, or cytarabine for the treatment of acute myeloid leukemia. The third is for the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. The fourth administers glasdegib to patients at high risk for relapse after stem cell transplants in acute lymphoblastic or myelogenous leukemia.

LCC's process chemistry team have developed highly efficient synthetic routes that provides access to Talazoparib and Glasdegib in >99% chemical purity and ee and has already been piloted on 100g scale. As a result, LCC can also provide the intermediates to aid analogue synthesis.

LCC will continue to apply its expertise in catalysis and chiral chemistry to produce building blocks, key intermediates and API. If you are interested in similar products and feel you could benefit from our services, I'd be delighted to talk with you.

Regards,

Paul Colbon (CEO and Co-founder, Liverpool ChiroChem).

